Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04390399
Title Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for First and Second Line Treatment of Locally Advanced or Metastatic Pancreatic Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors ImmunityBio, Inc.
Indications

pancreatic cancer

Therapies

Fluorouracil + Irinotecan + Leucovorin

Aldoxorubicin + ALT-803 + Cyclophosphamide + Gemcitabine + Nab-paclitaxel + PD-L1.t-haNK cells

Aldoxorubicin + Cyclophosphamide + Gemcitabine + Nab-paclitaxel

Aldoxorubicin + ALT-803 + Cyclophosphamide + Gemcitabine + Nab-paclitaxel

Cyclophosphamide + Gemcitabine + Nab-paclitaxel

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.